Pharmaceuticals and pharmaceutical products for treating friedreich's ataxia, huntington's disease, myotonic dystrophy, spinocerebellal ataxia, fragile-x syndrome and other neuromuscular, metabolic, autoimmune, cardiovascular, hyperplastic diseases that respond to ribonucleic acid (RNA)-based therapies; pharmaceuticals comprising drugs based on oligonucleotides and drugs that modulate RNA expression